Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired neurological disorder characterized clinically by weakness and impaired sensory function evolving over 2  months or more, loss or significant decrease in deep tendon reflexes, and by electrophysiological evidence of peripheral nerve demyelination. Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. Intravenous immunoglo bulin (IVIG) is one first-line and maintenance therapy option for CIDP.

Source: Journal of the Neurological Sciences - November 8, 2019 Category: Neurology Authors: Jeffrey A. Allen, Deborah F. Gelinas, Miriam Freimer, M. Chris Runken, Gil I. Wolfe Source Type: research